Herpes zoster or shingles affects 1 in every 3 adults, causing a painful rash that can result in long-term pain in 8% to 27% of people. New study finds the benefits of getting vaccinated against shingles.

‘New study concluded that the recombinant subunit zoster vaccine is more cost-effective for adults aged above 60 years and it provides more health benefits than the live attenuated zoster vaccine in Canada.’
Read More..

The number of people needed to be vaccinated to prevent one case of shingles was lower for RZV (Shingrix) than for LZV (Zostavax) for all ages. For example, in people aged 60 years, the number needed to vaccinate was 18 for RZV and 78 for LZV. Read More..





"Our model predicted that the recombinant subunit zoster vaccine is likely cost-effective in Canada for adults 60 years or older and that it provides greater health benefits than the live attenuated zoster vaccine for all age groups," writes Dr. Marc Brisson, Centre de research du Centre hospitalier de l'Université de Québec and the Université Laval, Québec, Quebec, with coauthors.
The study results are consistent with other economic evaluations in the United States and the Netherlands.
Source-Eurekalert